Transaction DateRecipientSharesTypePriceValue
27th January 2021Charles Theuer11,000Open or private purchase$8.98$98,771.20
29th December 2020Charles Theuer1,000Open or private purchase$9.98$9,980.00
10th December 2020Garry Arthur Neil3,599Open or private purchase$2.28$8,198.52
21st October 2020Charles Theuer2,000Open or private purchase$4.38$8,769.00
23rd September 2020Charles Theuer107Open or private purchase$4.72$505.05
23rd September 2020Charles Theuer4,893Open or private purchase$4.72$23,093.98
4th September 2020Charles Theuer5,000Open or private purchase$2.60$13,000.00
4th September 2020Charles Theuer5,000Open or private purchase$2.55$12,750.00
1st September 2020Michael G Carter71,429Open or private purchase$2.10$150,000.90
21st August 2020Charles Theuer5,325Open or private purchase$1.56$8,307.00
G Tx
G Tx logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

GTx, Inc. is a biopharmaceutical company. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.

Ticker: GTXI
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1260990
Employees: 21
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $17 M (0%)
Assets, Current: $18 M (-13%)
Other Assets, Noncurrent: $766 Th (0%)
Assets: $19 M (-13%)
Accounts Payable, Current: $1 M (68%)
Accrued Liabilities, Current: $4 M (0%)
Liabilities, Current: $9 M (22%)
Common Stock, Value, Issued: $17 Th (13%)
Common Stock, Shares, Issued: $17 Th (12%)
Retained Earnings (Accumulated Deficit): $76 M (0%)
Stockholders' Equity (Parent): $10 M (0%)
Liabilities and Equity: $19 M (-13%)
General and Administrative Expenses: $2 M (-52%)
Operating Income/Loss: $6 M (-46%)